As of Nov 19, 2026, 0 of 1 active firms rate LPCN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LPCN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.28 – $-0.28 · 1 analysts · -48% YoY
Next period, 1 analysts expect Lipocine Inc to earn $-0.28 a share (range $-0.28 – $-0.28), versus $-0.54 a year earlier. Full-year consensus is $-1.20, growing to $-1.22 the year after.
REVENUE · NEXT QUARTER
$100.0K
Range $100.0K – $100.0K · 1 analysts · -16% YoY
Revenue is expected to reach $100.0K (range $100.0K – $100.0K), -16.2% year-over-year. Full-year consensus is $509.0K, rising to $745.0K next year.
Top analysts covering Lipocine Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LPCN.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Neutral
$4.00+163.2% to target
Overall win rate
34%
+ Follow
#2
SH
Scott Henry
Alliance Global Partners
Buy
$6.00+294.7% to target
Coverage
—
+ Follow
LPCN stock forecast FAQ
What is LPCN's average 12-month price target?+
The 1 active firms with a live target average $4.00 for Lipocine Inc over the next 12 months, ranging from a $4.00 high to a $4.00 low, as of Nov 19, 2026.
Is LPCN stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover LPCN?+
1 active firms have a recognized rating on Lipocine Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LPCN?+
Among analysts who currently cover LPCN, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Neutral with a $4.00 target.
What is Lipocine Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.28 – $-0.28) across 1 analysts. Full-year EPS is projected at $-1.20, rising to $-1.22 the following year.
How much revenue is Lipocine Inc expected to report next quarter?+
Consensus revenue is $100.0K (range $100.0K – $100.0K). Full-year revenue is projected at $509.0K, growing to $745.0K next year.
Have analysts been upgrading or downgrading LPCN lately?+
As of Nov 19, 2026, 0 of 1 active firms rate LPCN a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LPCN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.